ArticleNature medicine2018
PM20D1 is a quantitative trait locus associated with Alzheimer's disease.
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 2 pooled it
5.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 2 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Distinct sex-specific DNA methylation differences in Alzheimer's disease.Alzheimer's research & therapy · 2022Pooled it
- Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer's disease.Nature communications · 2022Pooled it
- Immune cell-specific genetic architecture of Alzheimer's disease revealed by multi-omics analysis for therapeutic target discovery and prioritization.Translational psychiatry · 2026Article
- The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease.Cell death & disease · 2026Article
- A Tale of Monozygotic Twins With Down Syndrome: Divergent Clinical Paths to Dementia.Neurology open access · 2026Article
- Cell-type- and locus-specific epigenetic editing of memory expression.Nature genetics · 2025Article
- Manipulating Engram Histone Acetylation Alters Memory Consolidation.Hippocampus · 2025Article
- Bidirectional shifts in Pm20d1 expression impact thermogenesis and metabolism.Molecular medicine (Cambridge, Mass.) · 2025Article
- Hypermethylation ofJournal of the American Heart Association · 2025Article
- DNA Methylation in Alzheimer's Disease.Current topics in behavioral neurosciences · 2025Review
- Article
- Synaptic and extrasynaptic distribution of NMDA receptors in the cortex of Alzheimer's disease patients.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The PM20D1-NADA pathway protects against Parkinson's disease.Cell death and differentiation · 2024Article
- DNA Methylation Patterns Associated with Tinnitus in Young Adults-A Pilot Study.Journal of the Association for Research in Otolaryngology : JARO · 2024Article
- The Role of Magnesium in Parkinson's Disease: Status Quo and Implications for Future Research.International journal of molecular sciences · 2024Review
- Serum PM20D1 levels in patients with idiopathic pulmonary arterial hypertension and its clinical significance.BMC cardiovascular disorders · 2024Observational
- Accelerated epigenetic aging and DNA methylation alterations in Berardinelli-Seip congenital lipodystrophy.Human molecular genetics · 2023Article
- Neurofilament-light chain quantification by Simoa and Ella in plasma from patients with dementia: a comparative study.Scientific reports · 2023Article
- Systemic interindividual epigenetic variation in humans is associated with transposable elements and under strong genetic control.Genome biology · 2023Article
- Down-regulation of PM20D1 is associated with clinical outcomes and prognosis of pregnant patients with diabetes mellitus.Archives of medical science : AMS · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 7 institutions in 3 countries.
Jose V Sanchez-MutLaboratory of Neuroepigenetics, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9292-8521
Holger HeynCentro Nacional de Análisis Genómico (CNAG), Center for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain.ORCID http://orcid.org/0000-0002-3276-1889
Bianca A SilvaLaboratory of Neuroepigenetics, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Lucie DixsautLaboratory of Neuroepigenetics, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Paula Garcia-EsparciaDepartment of Pathology and Experimental Therapeutics, University of Barcelona, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
Enrique VidalCenter for Genomic Regulation, Barcelona Institute for Science and Technology, Barcelona, Spain.ORCID http://orcid.org/0000-0002-4217-1807
Sergi SayolsBioinformatics Core Facility, Institute of Molecular Biology, Mainz, Germany.ORCID http://orcid.org/0000-0002-3877-4170
Liliane GlauserLaboratory of Neuroepigenetics, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Ana Monteagudo-SánchezGenomic Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Institut d'Investigació Biomedica de Bellvitge, Barcelona, Spain.ORCID http://orcid.org/0000-0002-1432-1185
Jordi Perez-TurInstitut de Biomedicina de València-CSIC, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Investigación Sanitaria 'La Fe', València, Spain.ORCID http://orcid.org/0000-0002-9111-1712
Isidre FerrerDepartment of Pathology and Experimental Therapeutics, University of Barcelona, Institut d'Investigació Biomedica de Bellvitge (IDIBELL), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain.
David MonkGenomic Imprinting and Cancer Group, Cancer Epigenetics and Biology Program, Institut d'Investigació Biomedica de Bellvitge, Barcelona, Spain.
Bernard SchneiderNeurodegenerative Studies Laboratory, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.ORCID http://orcid.org/0000-0001-5485-8748
Manel EstellerCancer Epigenetics Group, Cancer Epigenetics and Biology Program, Institut d'Investigació Biomedica de Bellvitge, Barcelona, Spain.
Johannes GräffLaboratory of Neuroepigenetics, Brain Mind Institute, Faculty of Life Sciences, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland. johannes.graeff@epfl.ch.
École Polytechnique Fédérale de Lausanne · CHInstitut d'Investigació Biomédica de Bellvitge · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESBarcelona Institute of Science and Technology · ESCentro de Investigación Biomédica en Red · ESInstitute of Molecular Biology · DEUniversitat Pompeu Fabra · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chances to develop Alzheimer's disease (AD) result from a combination of genetic and non-genetic risk factors
Indexed as
AgedAlzheimer DiseaseAmidohydrolasesAmyloid beta-PeptidesAnimalsCell Line, TumorChromatinFemaleFrontal LobeGenome-Wide Association StudyHumansHydrogen PeroxideLinkage DisequilibriumMaleMiceMiddle AgedAmidohydrolasesAmyloid beta-PeptidesChromatinHydrogen PeroxidePM20D1 protein, human
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.